The Journal of Urology
Volume 178, Issue 6 , Pages 2337-2339 , December 2007

Holmium Laser Treatment for Low Grade, Low Stage, Noninvasive Bladder Cancer With Local Anesthesia and Early Instillation of Mitomycin C

Received 16 April 2007

References 

  1. Oosterlinck W, Van der Meijden A, Sylvester R, Böhle A, Rintala E, Solsona E, et al. Guidelines on TaT1 (Non-muscle invasive) bladder cancer (European Association of Urology). 2006;Available at http://www.uroweb.org/nc/professionalresources/guidelines/online/. Accessed June 27, 2007
  2. Johnson DE. Use of the holmium:YAG (Ho:YAG) laser for treatment of superficial bladder carcinoma. Lasers Surg Med. 1994;14:213
  3. Das A, Gilling P, Fraundorfer M. Holmium laser resection of bladder tumors (HoLRBT). Tech Urol. 1998;4:12
  4. Syed HA, Biyani CS, Bryan N, Brough SJ, Powell CS. Holmium:YAG laser treatment of recurrent superficial bladder carcinoma: initial clinical experience. J Endourol. 2001;15:625
  5. Hossain MZ, Khan SA, Salam MA, Hossain S, Islam R. Holmium YAG laser treatment of superficial bladder carcinoma. Mymensingh Med J. 2005;14:13
  6. Jønler M, Lund L, Bisballe S. Holmium:YAG laser vaporization of recurrent papillary tumours of the bladder under local anaesthesia. BJU Int. 2004;94:322
  7. Sylvester R, Oosterlinck W, van der Meijden A. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186
  8. Mostofi FK, Sorbin LH, Torloni H. Histological Typing of Urinary Bladder Tumours (International Classification of Tumours, 19). Geneva: World Health Organization; 1973;
  9. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients (Is it always safe?). Eur Urol. 2004;46:336
  10. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes A, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466

 Study received institutional review board approval.

PII: S0022-5347(07)02038-1

doi: 10.1016/j.juro.2007.08.034

The Journal of Urology
Volume 178, Issue 6 , Pages 2337-2339 , December 2007

Article Tools

* Image Usage & Resolution